QTRX logo

Quanterix Corporation (QTRX)

$2.86

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on QTRX

Market cap

$135788287

EPS

-2.35

P/E ratio

--

Price to sales

1.01

Dividend yield

--

Beta

1.050948

Price on QTRX

Previous close

$2.84

Today's open

$2.84

Day's range

$2.82 - $2.97

52 week range

$2.15 - $8.77

Profile about QTRX

CEO

Masoud Toloue

Employees

450

Headquarters

Billerica, MA

Exchange

NASDAQ Global Market

Shares outstanding

47478422

Issue type

Common Stock

QTRX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on QTRX

Quanterix Announces Leadership Transition Plan

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that Everett Cunningham has stepped down as President and Chief Executive Officer and as a member of the Company's Board of Directors (the “Board”), effective immediately, to accept an opportunity in another area of the healthcare sector. The Board has appointed Jim Gute, Quanterix's Chief Commercial Officer, to serve in the addi.

news source

Business Wire • 2 hours ago

news preview

Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced an exclusive distribution agreement with Sherman Abrams Laboratory, a Brooklyn-based clinical and anatomic pathology lab, to bring its LucentAD® Complete blood tests to patients across New Jersey and the surrounding area. LucentAD Complete from Quanterix is powered by the SIMOA® platform and is one of the first blood-based tests to screen for multiple biomarkers associated with Alzheimer's disease, helping p.

news source

Business Wire • Nov 16, 2026

news preview

What Quanterix (QTRX) Said on Its Q3 Earnings Call

Quanterix NASDAQ: QTRX reported third-quarter revenue of $35 million, up 6.3% from the previous quarter but down 13.1% from a year earlier, as stronger spatial consumables sales helped the company exceed its own expectations.

news source

MarketBeat • Nov 9, 2026

news preview

Quanterix Corporation (QTRX) Q3 2026 Earnings Call Transcript

Quanterix Corporation (QTRX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 9, 2026

news preview

Quanterix Releases Financial Results for the Third Quarter of 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the third quarter ended September 30, 2026. “We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercia.

news source

Business Wire • Nov 9, 2026

news preview

Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET, to discuss its third quarter 2026 financial results. Quanterix will issue a press release regarding its third quarter 2026 financial results prior to the conference call on Monday, November 9, 2026. The press release will be posted on the Quanterix website at http://www.quanterix.c.

news source

Business Wire • Oct 28, 2026

news preview

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

BILLERICA, Mass. & BEIJING--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market. Initially formed in 2024, the commercialization arrangement combines Quanterix's ultra-sensitive biomarker de.

news source

Business Wire • Oct 7, 2026

news preview

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on the.

news source

Business Wire • Sep 25, 2026

news preview

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the “Inducement Grants”) were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units (“RSUs”) representing 260,315 shares of Qua.

news source

Business Wire • Sep 17, 2026

news preview

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company's Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix's innovative technologies and application.

news source

Business Wire • Sep 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Quanterix Corporation

Open an M1 investment account to buy and sell Quanterix Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in QTRX on M1